Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
What Should I Do With Credit Card Points
Learn the best actions to take with your credit card points. Make informed decisions to maximize your rewards and benefits.
25,531 articles
Kalshi’s Brazil Prediction Market Launch Sparks Debate
Kalshi launches its Brazil prediction market through XP International, reframing macro bets as regulated derivatives....
Retail Investors Showing Signs of Fatigue as Iran Risks Grow
JPMorgan warns that retail investors showing signs of fatigue could temper stock demand as Iran-related tensions inte...
Remitly (RELY) 2025 Earnings Guide for Investors: Insights
Remitly (RELY) is evolving beyond simple transfers. This in-depth analysis walks through expected 2025 earnings drive...
Codere Online CEO: Online Growth in LATAM Accelerates
Codere Online reports a record Q4 2025, powered by Mexico growth and a rising active user base. The company outlines ...
Invested $1,000 McDonald’s Starbucks: A Decade of Gains
A look at how a $1,000 stake in McDonald’s versus Starbucks would have evolved over the past decade, with today’s mar...
Palantir CTO: U.S. Only Sparks Defense Readiness Debate
Palantir's chief technology officer raised alarms about U.S. weapon stock levels in a recent discussion, prompting re...
Bitcoin Whales Abandon Ship as BTC Dips Below $70K
Bitcoin briefly trades under $70,000 as major BTC wallets unload large holdings. While some OGs exit, others continue...
Tesla Has Lots Irons in the Fire, Yet Quiet Stock
Tesla's stock has traded with unusual calm as the company advances robotaxis and semiconductor initiatives. Early pil...
Rethinking Diversification: Where Blue-Chip Art Fits In
Investors are increasingly adding blue-chip art to mainstream portfolios to diversify beyond stocks and bonds. Fracti...
Amazon Ready to Take Starlink in Space Broadband Race
Amazon unveils a bold plan to expand Leo satellites, targeting 1 Gbps speeds and enterprise deals that could disrupt ...
Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status